stockrow
Monday 9 November 2026
Export FATE’s income statement to Excel — free account
Fate Therapeutics, Inc.
FATEFate Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.6 million, down 51.2% from fiscal 2024.
- Revenue
- +9.18%
- EPS
- +13.8%
- Free cash flow
- +8.96%
Quarter to June 2026, against a year earlier
1.84
0.01
−0.54%
Follow FATE
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
50.08 | 22.81 | 17.52 | 21.01 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(13.87) | (4.67) | (4.99) | (6.15) | |
P/B ratio |
2.12 | 0.80 | 0.56 | 0.64 | |
Price to Tangible BV |
2.12 | 0.80 | 0.56 | 0.64 | |
EV/Sales |
30.00 | (1.17) | (9.61) | (5.90) | |
EV/EBITDA |
0.00 | 0.06 | 0.46 | 0.26 | |
EV/Operating CF |
(1.91) | 0.07 | 0.60 | 0.38 | |
EV/FCF |
(1.85) | 0.07 | 0.57 | 0.37 | |
Quick Ratio |
4.74 | 5.72 | 5.67 | 7.69 | |
Current Ratio |
4.85 | 5.85 | 5.79 | 7.87 | |
Net Debt/EBITDA |
5.28 | 5.67 | 6.26 | 6.67 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.02 | 0.02 | 0.02 | 0.02 | |
Operating CF/Net income |
0.78 | 0.99 | 0.72 | 0.76 | |
Capex/Depreciation |
(0.04) | (0.11) | (0.44) | (0.91) | |
Research and Development Expense of Revenue |
1,171.33% | 1,901.69% | 1,857.20% | 1,484.09% | |
Selling, General and Administrative Expense of Revenue |
424.06% | 738.72% | 779.04% | 611.03% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
168.97% | 302.46% | 403.80% | 279.21% | |
Graham Net Nets |
0.16 | 0.52 | 0.83 | 0.74 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(38.89%) | (90.83%) | (117.35%) | (104.76%) | |
Free Cash Flow Yield |
(32.43%) | (74.79%) | (95.93%) | (76.90%) | |
Revenue per Share |
0.02 | 0.01 | 0.01 | 0.01 | |
Operating CF per Share |
(0.19) | (0.26) | (0.20) | (0.20) | |
Capex per Share |
0.00 | 0.00 | (0.01) | (0.02) | |
Free Cash Flow per Share |
(0.20) | (0.26) | (0.20) | (0.22) | |
Cash per Share |
1.28 | 1.46 | 1.71 | 1.81 | |
Shareholders Equity per Share |
1.27 | 1.50 | 1.74 | 1.97 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.27 | 1.50 | 1.74 | 1.97 | |
Free Cash Flow |
(23.51) | (31.06) | (24.27) | (26.57) | |
Working Capital |
125.36 | 148.84 | 172.63 | 193.14 | |
Capital Expenditures |
(0.08) | (0.24) | (0.95) | (2.20) | |
Net Current Asset Value |
51.29 | 74.32 | 96.95 | 111.65 | |
EV/EBIT |
0.00 | 0.05 | 0.43 | 0.24 | |
Capex to Sales |
0.04 | 0.18 | 0.70 | 1.26 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.05 | 1.56 | 2.23 | 2.40 | |
Average Payables |
3.65 | 3.73 | 6.01 | 4.93 | |
Average Assets |
315.87 | 341.79 | 379.82 | 419.32 | |
Average Common Equity |
207.40 | 234.06 | 262.95 | 298.19 |
Columns are period end dates